Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Progression-Free Survival
Interventions
DRUG

Metformin Pill

Metformin 500mg TID、FOLFIRI (Leucovorin 200 mg/m2、5-FU 2800 mg/m2、Irinotecan 180 mg/m2) plus target therapy

DRUG

FOLFIRI plus target therapy only

FOLFIRI (Leucovorin (LV), 200 mg/m2, 2-hour infusion, 5-FU, 2,800 mg/m2, 46-hour infusion, Irinotecan (IRI), 180 mg/m2, 2-hour infusion) plus target therapy

Trial Locations (1)

807

RECRUITING

Chung-Ho Memorial Hospital, Kaohsiung Medical University:, Kaohsiung City

All Listed Sponsors
lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER